Physician profile
Bobby J Smith
NPI 1427556679
$14,926.89
in general payments reported to CMS, 2019-2025
30 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,671 · 2022: $2,054 · 2023: $4,557 · 2024: $4,756 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,105 · Consulting Fee: $3,300 · Travel and Lodging: $624 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,104.54 |
| Consulting Fee | $3,300.00 |
| Travel and Lodging | $623.84 |
| Education | $173.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $5,061.30 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $3,318.31 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,168.82 | 2021-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $1,026.96 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $726.06 | 2021-2025 | Saphnelo |
| Amgen INC. | $653.11 | 2021-2025 | Enbrel, Otezla, Tavneos |
| E.R. Squibb & Sons, L.L.C. | $598.00 | 2021-2025 | Orencia |
| Pfizer INC. | $588.28 | 2021-2025 | |
| Ucb, INC. | $354.89 | 2021-2025 | Cimzia, Bimzelx |
| Intuitive Surgical, INC. | $238.88 | 2023 | Da Vinci Surgical System |
| Lilly USA, LLC | $198.77 | 2021-2023 | Taltz |
| Genzyme Corporation | $114.86 | 2025 | |
| Mallinckrodt Hospital Products INC. | $105.25 | 2023-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $102.20 | 2023-2024 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $93.48 | 2023-2024 | Strensiq, Ultomiris |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $82.85 | 2022-2024 | Lupkynis |
| Fresenius Kabi USA, LLC | $71.43 | 2023-2024 | Idacio |
| Scilex Pharmaceuticals INC. | $52.87 | 2024-2025 | |
| Organon LLC | $49.45 | 2023-2025 | Hadlima |
| Atricure, INC. | $41.74 | 2024-2025 | Synergy Ablation System |
| Celltrion USA INC. | $39.51 | 2023 | Yuflyma |
| Genentech USA, INC. | $38.86 | 2023-2024 | Actemra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.23 | 2023-2024 | Cyltezo |
| Kyowa Kirin, INC. | $36.63 | 2023-2024 | Crysvita |
| Sandoz INC. | $31.51 | 2023 | Hyrimoz |
| Mylan Institutional INC. | $21.79 | 2023 | Hulio |
| Radius Health, INC. | $19.34 | 2021 | |
| Sobi, INC | $18.33 | 2022 | |
| Alvogen INC | $17.82 | 2025 | Teriparatide |
| Kiniksa Pharmaceuticals International, Plc | $17.36 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.